Document is current
Any future updates will be listed below
-
Authors
,
Polimanti, Renato
Amstadter, Ananda B.
Stein, Murray B.
Almli, Lynn M.
Baker, Dewleen G.
Bierut, Laura J.
Bradley, Bekh
Farrer, Lindsay A.
Johnson, Eric O.
King, Anthony
Kranzler, Henry R.
Maihofer, Adam X.
Rice, John P.
Roberts, Andrea L.
Saccone, Nancy L.
Zhao, Hongyu
Liberzon, Israel
Ressler, Kerry J.
Nievergelt, Caroline M.
Koenen, Karestan C.
Gelernter, Joel
-
Funding
Funding for this research was provided by:
National Institute of Mental Health (R01 MH106595, U01 MH109532)
U.S. Department of Veterans Affairs (National Center for PTSD Research)
- License Information
-
More Information
Article History
Received: 28 July 2017
Accepted: 6 November 2017
First Online: 27 November 2017
Ethics approval and consent to participate
: This study is based on the PGC-PTSD data freeze 1, which is an anonymized dataset. The cohorts contributing to the PGC-PTSD workgroup included in the present analysis are: Collaborative Genetic Study of Nicotine Dependence; Family Study of Cocaine Dependence; Yale-Penn; Grady Trauma Project; Marine Resilience Study; Nurses’ Health Study; and Ohio National Guard. Each of the contributing studies has an institutional review board-approved protocol to investigate the genetics of PTSD and provided the data consistent with their approved protocols. All studies involved in the PGC-PTSD workgroup comply with the Declaration of Helsinki. Additionally, we used GWAS summary statistics from the GIANT, Reprogen, and SSGAC consortia, which shared this information in accordance with the protocols approved for the cohorts participating in these studies.
: Not applicable.
: Dr. Stein has in the last three years been a consultant for Actelion Pharmaceuticals, Healthcare Management Technologies, Janssen, Pfizer, Resilience Therapeutics, Tonix Pharmaceuticals, and Oxeia Biopharmaceuticals. Dr. Kranzler has been an advisory board member, consultant, or CME speaker for Indivior and Lundbeck. He is also a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative, which was supported in the last three years by AbbVie, Alkermes, Ethypharm, Indivior, Lilly, Lundbeck, Pfizer, Arbor, and Amygdala Neurosciences. Dr. Bierut is listed as an inventor on Issued US Patent 8,080,371, “Markers for Addiction” covering the use of certain SNPs in determining the diagnosis, prognosis, and treatment of addiction. Dr Liberzon has been a consultant for ARMGO Pharmaceutical, Sunovion Pharmaceutical, and Trimaran Pharma. The remaining authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
